Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
PD-L1 underexpression
i
Other names:
PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
29126
Related biomarkers:
Expression
Mutation
CNA
Others
‹
›
Associations
(46)
News
Trials
Search handles
@DrJNaidoo
@FilippoPietran4
@HeadNeckMD
@JackWestMD
@Latinamd
@StephenVLiu
@chulkimMD
@ipreeshagul
@sonpavde
Search handles
@DrJNaidoo
@FilippoPietran4
@HeadNeckMD
@JackWestMD
@Latinamd
@StephenVLiu
@chulkimMD
@ipreeshagul
@sonpavde
Filter by
Latest
9ms
Dr. @HosseinBorghaei joins #DCLung23 on October 7, 2023. A pioneer in the field of #immunotherapy for lung cancer, Dr. Borghaei will discuss management of PD-L1 low and negative NSCLC. Chemo-IO vs dual-checkpoint? Full agenda, faculty and registration at: https://t.co/rJa81GX23a (@StephenVLiu)
9 months ago
PD-L1 (Programmed death ligand 1)
|
PD-L1 underexpression • PD-L1-L
11ms
Dr. @LuisPaz_Ares makes the case for upfront CTLA4 therapy and dual checkpoint blockade for NSCLC at #RomeLung23. Particularly relevant for PDL1 low, where chemo-immunotherapy less effective long term, and not for PDL1 high, based on KN-598. Mixed results by histology. (@StephenVLiu)
11 months ago
Clinical • Checkpoint inhibition • Checkpoint block
|
PD-L1 underexpression • PD-1-L • PD-L1-L
1year
📣 Crowd- Sourcing #lcsm for my upcoming @IASLC #TTLC23 debate with the Great @HosseinBorghaei on Immunotherapy> 2 yrs. 60M w Stage IV NSCLC 🫁PDL1 low, no irAES, stable disease after 2 yrs of IO, Pt wishes to continue. What do you recommend? 👇🏽 @DrSteveMartin @CharuAggarwalMD… https://t.co/Yq9ujay6qD (@Latinamd)
1 year ago
Clinical • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 underexpression • PD-1-L • PD-L1-L
1year
A pleasure to review for @NatureComms Clinicogenomic features of response to chemo-IO in nsclc @NIVokes @MDAndersonNews - Chemo-IO mitigates early progression in high-risk pts (PDL1 low, STK11, never smokers, liver mets) - CDKN2 alteratns assoc w poor outcome @OncoAlert #LCSM (@DrJNaidoo)
1 year ago
Clinical • Review
|
PD-L1 (Programmed death ligand 1) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
|
PD-L1 underexpression • PD-1-L • PD-L1-L
1year
As presented by Dr. @peters_solange at #ESMO22, adjuvant pembrolizumab had a DFS HR 0.82 in PDL1 high, 0.67 in PDL1 low and 0.78 in PDL1 negative. Different from IMpower 010 where greatest benefit was in PDL1 high subset (DFS HR 0.43), which aligns more to expectations. #LCSM (@StephenVLiu)
1 year ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 underexpression • PD-L1 negative • PD-1-L • PD-L1-L
|
Keytruda (pembrolizumab)
over1year
KMs in unreported PDL1 low subgroups of pts with ESCC on ICI ➡️TPS is an important selection biomarker in line with EMA approval ➡️PD-L1 is less important in Asian pts! ➡️future: harmonize PDL1 test TY Singapore group @sundar__raghav @dominicyap_ https://t.co/fntQZtHE9S @JAMAOnc (@FilippoPietran4)
over 1 year ago
Clinical • European regulatory • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 underexpression • PD-1-L • PD-L1-L
over1year
Which role for 1st line single agent #IO in PDL1 low-neg #NSCLC? Take a look to our #PEOPLE trial results @ESMO_Open Circu lating immune subsets as useful biomarkers for ICI efficacy! https://t.co/T11BPHo9Dm @GLoRussoMD_PhD @PrelajArsela @marinagarassino (@saramanglaviti)
over 1 year ago
Clinical • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 underexpression • PD-1-L • PD-L1-L
over1year
Avelumab/axitinib in B3 thymoma & thymic carcinoma (CAVEATT) N=32 (thymic carcinoma majority) ORR=34% Similar PFS between between PD-L1 high vs. PD-L1 low/negative is notable Incidence of serious irAEs=12% (similar to PD-1 monoTx) @TheLancetOncol https://t.co/LQL8ueEWJQ (@chulkimMD)
over 1 year ago
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
PD-L1 underexpression • PD-L1 negative
|
Bavencio (avelumab) • Inlyta (axitinib)
over1year
For PD-L1 high might what’s happening yea Though one could argue that might not be the case for the majority of NSCLC pts that are PD-L1 low, where response to Pembro is significantly lower than for melanoma (@CGrassberger)
over 1 year ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 underexpression
|
Keytruda (pembrolizumab)
over1year
I think we can conclude that if there were going to be an impressive OS benefit in PD-L1+, we wouldn't have to debate it today. *There's an OS benefit for atezo in pts w/high PD-L1, no benefit for pts w/PD-L1 low or neg, as is consistent w/KN-042 & other work in adv NSCLC. (@JackWestMD)
over 1 year ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 underexpression
|
Tecentriq (atezolizumab)
almost2years
I offer adjuvant nivo to high risk urothelial carcinoma per CHECKMATE274-not enthusiastic in upper tract+PD-L1 low+no neoadjuvant chemo (NAC)-if no prior NAC: adjuvant cis if cis-eligible, nivo v gem-carbo based on PD-L1 expression if cis-ineligible? @MattGalsky @AlisonBirtle (@sonpavde)
almost 2 years ago
Clinical • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 underexpression
|
Opdivo (nivolumab)
2years
#TTLC22 P12 by Dr. @alissajcooper describes #KRAS G12D mutant cancers at MGH. Most common was pancreas followed by NSCLC. Among lung: 16% never smokers, skew toward PDL1 low or negative. Heat map shows co-mutations common in RAS/MAPK, PI3K, cell cycle and wnt pathways. (@StephenVLiu)
2 years ago
IO biomarker
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12D • PD-L1 underexpression • KRAS G12 • PD-1-L
2years
#TTLC22 In P09, Dr. Yunan Nie reports high PDL1 expression in patients with #ALK NSCLC linked to worse prognosis on ALK TKI. No difference in RR but PFS much shorter in PDL1 high (14m) vs PDL1 low/neg (54m). Prognostic power, but biologically, how is PDL1 linked to resistance? (@StephenVLiu)
2 years ago
Clinical • IO biomarker
|
PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression • PD-L1 overexpression • PD-L1 underexpression • PD-1-L
over2years
Excited to be presenting on #poseidon at the #NYLCF meeting @NickRohsMD @kaushalpar @VoglNY @HaiyingCheng @BHenickMD @JyotiMalhotraMD @fred_hirsch #LCSM - PFS benefit in Durva + CT vs CT alone - PFS & OS benefit in durva + trem + CT vs CT alone - benefit in adeno ca pdl1 low (@ipreeshagul)
over 2 years ago
PD-L1 (Programmed death ligand 1)
|
PD-L1 underexpression • PD-1-L
over2years
#ESMO21 Important update here. Would like to see data on MRD. Overall, I feel IMp010 is enough to change practice - hoping for regulatory decision in the near future. I would feel appropriate for PDL1 high and worth individual discussion in PDL1 low. #LCSM @myESMO (@StephenVLiu)
over 2 years ago
PD-L1 (Programmed death ligand 1)
|
PD-L1 underexpression • PD-1-L
over2years
#ESMO21 This is the NEW data we've been waiting for. DFS in PDL1 high was 0.43 and DFS in PDL1 low 0.87. Probably where most of us guessed it would land. Excluding EGFR/ALK appropriate since we're pursuing different strategies here so OS HR 0.82 more impactful. #LCSM @myESMO (@StephenVLiu)
over 2 years ago
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
|
PD-L1 underexpression • PD-1-L
almost3years
#ASCO21 Looking at subgroups of the all-randomized stage II-IIIA dataset, we see greater DFS benefit for PDL1 high (TC, SP263) with HR 0.43 compared to 0.66 for PDL1 positive and 0.97 for PDL1 negative. What we need to see is PDL1 low (1-49%). #LCSM (@StephenVLiu)
almost 3 years ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 underexpression • PD-L1 negative • PD-1-L
|
VENTANA PD-L1 (SP263) Assay
almost3years
#ASCO21 Pooled analysis of PDL1 low, excluding #EGFR and #ALK. Included landmark trials that established use. Note - seems like you can do some really cool powerful research at @FDAOncology these days! #LCSM (@StephenVLiu)
almost 3 years ago
Retrospective data
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
|
PD-L1 underexpression • PD-1-L
almost3years
#ASCO21 As one would expect, chemo/IO seems a stronger strategy in PDL1 low NSCLC, for both PFS and OS, though less so for older pts. Results are hypothesis generating but consistent with most of our practices. For PDL1 low, I favor chemo/IO or nivo/ipi. #LCSM @OncoAlert (@StephenVLiu)
almost 3 years ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 underexpression • PD-1-L
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
almost3years
#ASCO21 Dr. Oladimeji Akinboro with @FDAOncology presents a pooled analysis of chemo/IO vs IO alone for 1L treatment of PDL1 low (1-49%) NSCLC. With lack of head to head trials in this subset, this is a useful dataset. #LCSM @OncoAlert @harpreet_md (@StephenVLiu)
almost 3 years ago
Retrospective data • Head-to-Head
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 underexpression • PD-1-L
almost3years
Compelling data in 1L R/M #SCCHN for Pembro+CTX -- notable oral cavity, PD-L1 low/negative benefit. 🧐👀🩺@DrEzraCohen @DrUppaluri @DF_HeadandNeck https://t.co/mgCVe7k5g8 (@HeadNeckMD)
almost 3 years ago
PD-L1 (Programmed death ligand 1)
|
PD-L1 underexpression • PD-L1 negative
|
Keytruda (pembrolizumab)
almost3years
Updated OS data. Pembro improved OS in ITT (median 22.0m vs 10.6m, HR 0.56) and across PDL1 strata. In PDL1 high: mOS 27.7m vs 10.1m (HR 0.59). In PDL1 low: mOS 21.8m vs 12.1m (HR 0.66). In PDL1 negative: mOS 17.2 vs 10.2m (HR 0.51). Benefit in PDL1 0% important to remember #LCSM (@StephenVLiu)
almost 3 years ago
PD-L1 (Programmed death ligand 1)
|
PD-L1 underexpression • PD-L1 negative • PD-1-L
|
Keytruda (pembrolizumab)
almost4years
Interesting data on PD-L1 expression in nsclc shows: - PD-L1 (-) more common in primary v metastatic sites; LN PD-L1 high, bones PD-L1(-), relationship btwn PD-L1 expression & ICI response varied by organ. KRAS, TP53, MET associated with PD-L1 high; EGFR, STK11 with PD-L1 low (@DrJNaidoo)
almost 4 years ago
PD(L)-1 Biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11)
|
PD-L1 expression • PD-L1 underexpression
almost4years
#ASCO20 Randomized 135 patients, 43% PDL1 high. Tiragolumab improved RR (37% vs 21%). In PDL1 TPS 50%+, RR 66% vs 24% (in PDL1 low, RR 16% vs 18%). Median f/u only 10.9m so need more time but the control arm does appear a bit worse than we would expect. #OncoAlert #LCSM (@StephenVLiu)
almost 4 years ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 underexpression • PD-1-L
|
tiragolumab (RG6058)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login